Drug Profile
Dexecadotril - Bioprojet
Alternative Names: RetorphanLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Bioprojet
- Class Analgesics; Antidiarrhoeals
- Mechanism of Action Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal disorders
Most Recent Events
- 11 Oct 2021 Phase III development is ongoing in France (Bioprojet pipeline, October 2021)
- 05 Sep 2018 Phase III development is ongoing in France (Bioprojet pipeline, September 2018)
- 26 Nov 2015 Phase III development is ongoing in France